

ARKANSAS Diabetes Data & Forecasts

State Total Population Forecasts	2015	2020	2025	2030
Entire Population	2,968,900	3,060,200	3,151,000	3,240,200
Prediabetes	819,400	872,500	925,200	952,700
Diagnosed diabetes	278,200	339,600	393,100	436,500
Undiagnosed diabetes	86,300	100,100	109,900	115,600
Total with diabetes (diagnosed and undiagnosed)	364,500	439,700	503,000	552,100
Complications:				
Visual impairment	45,600	54,100	60,700	65,500
Renal failure	660	780	870	930
Leg amputations	580	650	690	700
Annual deaths attributable to diabetes	3,000	3,490	3,840	4,040
Total annual cost (2015 dollars)	\$3.5 B	\$4.2 B	\$4.8 B	\$5.3 B
Annual medical costs	\$2.5 B	\$3.0 B	\$3.5 B	\$3.8 B
Annual nonmedical costs	\$1.0 B	\$1.2 B	\$1.3 B	\$1.5 B

State Senior Population Forecasts	2015	2020	2025	2030
Population 65 and older	467,900	531,000	599,000	656,400
Prediabetes	238,600	270,800	305,500	334,800
Diagnosed diabetes	88,400	100,300	113,200	124,100
Undiagnosed diabetes	32,800	37,200	41,900	45,900
Total with diabetes (diagnosed and undiagnosed)	121,200	137,500	155,100	170,000
Complications:				
Visual impairment	16,500	18,300	20,100	21,500
Renal failure	270	300	330	340
Leg amputations	200	210	220	230
Annual deaths attributable to diabetes	2,070	2,340	2,490	2,540
Total annual cost (2015 dollars)	\$1.5 B	\$1.8 B	\$2.0 B	\$2.2 B
Annual medical costs	\$1.4 B	\$1.7 B	\$1.9 B	\$2.1 B
Annual nonmedical costs	\$0.1 B	\$0.1 B	\$0.1 B	\$0.1 B

These forecasts are based on the latest available national diabetes data, including U.S Census Bureau population projections, the CDC National Diabetes Statistics Report, 2014, CDC diabetes morbidity trend reports, CDC's latest diabetes prevalence projections to 2050 and Dall, et al. "The Economic Burden of Elevated Blood Glucose Levels in 2012: Diagnosed and Undiagnosed Diabetes, Gestational Diabetes Mellitus, and Prediabetes," *Diabetes Care* 2014;37:3172-3179. These forecasts assume a steady, but conservative, reduction in the number of people with complications due to better awareness of the risks of diabetes, earlier screening and intervention, and more effective therapies.

For details and references on the Institute for Alternative Futures Diabetes 2030 Forecasting Model Methodology, visit www.altfutures.org/diabetes2030.

Research funded by Novo Nordisk Inc.